Premium
CD16 + monocytes in human cutaneous leishmaniasis: increased ex vivo levels and correlation with clinical data
Author(s) -
Soares George,
Barral Aldina,
Costa Jackson M.,
BarralNetto Manoel,
Van Weyenbergh Johan
Publication year - 2006
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.0105040
Subject(s) - cd16 , ex vivo , immunology , biology , leishmaniasis , in vivo , monocyte , leishmania , medicine , immune system , cd3 , cd8 , parasite hosting , microbiology and biotechnology , world wide web , computer science
Peripheral blood CD16 (Fc receptor for immunoglobulin G III)‐positive monocytes have been shown to expand in different pathological conditions, such as cancer, asthma, sepsis, human immunodeficiency virus infection, and AIDS progression, but data in leishmaniasis are lacking. We found that cutaneous leishmaniasis patients (n=15) displayed a significant increase in the ercentage (3.5 vs. 10.1) as well as mean fluorescent intensity (13.5 vs. 29.2) of ex vivo CD16 expression in monocytes as compared with healthy controls. We observed a significant positive correlation between the percentage of ex vivo CD16 + monocytes and lesion size ( P =0.0052, r=0.75) or active transforming growth factor‐β plasma levels ( P =0.0017, r=0.78). In addition, two patients with nonhealing lesions during a 3‐year follow‐up had high (9.1–19.4%) CD16 levels at diagnosis. Our data suggest a deleterious role for CD16 in human leishmaniasis, as well as its possible use as a marker for disease severity and/or adverse disease outcome.